ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,463.54
      0.08%
      US Tech 100
      18,493.20
      -0.14%
      Dow Jones
      40,539.93
      -0.12%
      Brent Oil
      78.88
      -0.33%
      Bitcoin
      66,383.94
      -0.66%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Neurogene Inc (NGNE) Quote

      Neurogene Inc

      Neurogene Inc (NGNE)

      NASDAQ
      41.35
      -3.48
      (-7.76%)
      Closed July 29 4:00PM
      Delayed by 15 minutes
      41.35
      0.00
      (0.00%)
      After Hours: 5:14PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      41.35
      Bid
      40.00
      Ask
      45.30
      Volume
      146,182
      39.8301 Day's Range 46.9999
      12.49 52 Week Range 53.00
      Market Cap
      536.735M
      Previous Close
      44.83
      Open
      44.96
      Last Trade
      4
      @
      41.31
      Last Trade Time
      Financial Volume
      $ 6,216,934
      VWAP
      42.5287
      Average Volume (3m)
      98,536
      Shares Outstanding
      12,980,289
      Dividend Yield
      -
      PE Ratio
      -1.25
      Earnings Per Share (EPS)
      -2.8
      Revenue
      -
      Net Profit
      -36.32M

      About Neurogene Inc

      Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit o... Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.neoleukin.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Neurogene Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NGNE. The last closing price for Neurogene was $44.83. Over the last year, Neurogene shares have traded in a share price range of $ 12.49 to $ 53.00.

      Neurogene currently has 12,980,289 shares outstanding. The market capitalization of Neurogene is $581.91 million. Neurogene has a price to earnings ratio (PE ratio) of -1.25.

      NGNE Latest News

      More News

      FeaturedCannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA

      11 hours ago

      Holland & Knight Deploys the iManage WorkSite Suite to More than 3,000 Users in 30 Offices Worldwide

      Holland & Knight Deploys the iManage WorkSite Suite to More than 3,000 Users in 30 Offices Worldwide iManage Partner Baker Robbins & Company's Expertise Enables Rapid Conversion of More Than 10...

      November 12 2003
      PR Newswire (US)

      iManage E-mail Management Solution Being Deployed Nationwide

      iManage E-mail Management Solution Being Deployed Nationwide Law Firms Turn to iManage for Comprehensive Solution to Control E-mail Overload FOSTER CITY, Calif., Nov. 11 /PRNewswire-FirstCall/...

      November 11 2003
      PR Newswire (US)

      iManage Offers Full CAD Integration for the iManage WorkSite MP Suite

      iManage Offers Full CAD Integration for the iManage WorkSite MP Suite iManage to OEM McLaren Software to Link iManage WorkSite with AutoCAD and MicroStation FOSTER CITY, Calif., Nov. 10...

      November 10 2003
      PR Newswire (US)

      iManage CIO Survey Results Reveal Top Legal IT Priorities Entering 2004

      iManage CIO Survey Results Reveal Top Legal IT Priorities Entering 2004 Report Finds Firms Focusing on Greater Client Transparency, Business Continuity Planning and Matter Centric Collaboration...

      November 06 2003
      PR Newswire (US)

      iManage Announces Integrated Support for Adobe Acrobat

      iManage Announces Integrated Support for Adobe Acrobat New Capabilities Extend Comprehensive Management of PDF Documents Within iManage WorkSite FOSTER CITY, Calif., Nov. 5...

      November 05 2003
      PR Newswire (US)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.91-2.1533364884142.2646.999939.830113318343.42835512CS
      44.9613.630118164336.3949.0533.6712800341.78682307CS
      124.612.517006802736.7549.0529.549853637.62783263CS
      269.0928.177309361432.265328.0911921738.25259773CS
      5226.78183.80233356214.575312.4911281636.56986105CS
      15626.78183.80233356214.575312.4911281636.56986105CS
      26026.78183.80233356214.575312.4911281636.56986105CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      TWOU2U Inc
      $ 2.70
      (116.00%)
      		139.18M
      LIPOLipella Pharmaceuticals Inc
      $ 0.8576
      (112.22%)
      		194.69M
      NIPGNIP Group Inc
       16.50
      (82.93%)
      		7.04M
      TIVCTivic Health Systems Inc
      $ 0.7049
      (55.95%)
      		106.15M
      ISPOInspirato Inc
      $ 5.15
      (47.99%)
      		6.24M
      CGTXCognition Therapeutics Inc
      $ 1.32
      (-44.30%)
      		26.32M
      GRIGRI Bio Inc
      $ 0.8334
      (-33.86%)
      		1.14M
      CEROCERo Therapeutics Holdings Inc
      $ 0.1817
      (-29.02%)
      		8.28M
      PRSTPresto Technologies Inc
      $ 0.0499
      (-26.51%)
      		29.32M
      TGLTreasure Global Inc
      $ 1.40
      (-24.32%)
      		80.79k
      NVDANVIDIA Corporation
      $ 111.59
      (-1.30%)
      		248.03M
      LIPOLipella Pharmaceuticals Inc
      $ 0.8576
      (112.22%)
      		194.69M
      SQQQProShares UltraPro Short QQQ
      $ 9.05
      (-0.55%)
      		152.03M
      TWOU2U Inc
      $ 2.70
      (116.00%)
      		139.18M
      TSLATesla Inc
      $ 232.10
      (5.60%)
      		129.2M

      NGNE Discussion

      View Posts
      LegendaryNomad22 LegendaryNomad22 1 month ago
      Weird. Both TSHA and NGNE have gene therapy candidates for Rett and both of them tanked today, despite sharing strong interim results. There's an International Rett Syndrome Foundation meeting today and tomorrow, so I wonder if something happened there to take the wind out of the gene therapy treatment class. Anyone have any knowledge here?
      👍️0
      Monksdream Monksdream 4 months ago
      NGNE new 52 hi
      👍️0

      Your Recent History

      NASDAQ
      NGNE
      Neurogene
      Delayed Upgrade Clock